TABLE 1.

Dupilumab treatment groups presented

Pooled approved doses	Pooled other doses studied	All doses (approved + other) a
LIBERTY AD PEDS (aged 6–11)
200 mg q2w (≥30 kg)	100 mg q2w (<30 kg)	100/200 mg q2w
300 mg q4w b , c		300 mg q4w
LIBERTY AD ADOL (aged 12–17)
200 mg q2w (<60 kg)	300 mg q4w	200/300 mg q2w
300 mg q2w (≥60 kg)		300 mg q4w

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; q2w, every 2 weeks; q4w, every 4 weeks.

^a All doses include both approved doses and other doses studied as per the LIBERTY AD PEDS and LIBERTY AD ADOL study designs.

^b FDA approved for children (aged 6–11 years) <30 kg, and EMA approved for children (aged 6–11 years) 15–60 kg.

^c Per EMA recommendation, the dose may be increased to 200 mg every other week based on the doctor's opinion.